Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation

被引:16
作者
Altimari, A
Gruppioni, E
Fiorentino, M
Petraroli, R
Pinna, AD
Petropulacos, K
Ridolfi, L
Costa, AN
Grigioni, WF
Grigioni, AD
机构
[1] Ctr Riferimento Trapianti Emilia Romagna, Mol & Transplantat Pathol Lab F Addarii, Inst Oncol, Bologna, Italy
[2] Applera Italia, Monza, Italy
[3] Univ Bologna, S Orsola M Malpighi Hosp, Dept Surg, Bologna, Italy
[4] Assessorato Sanita Reg Emilia Romagna, Bologna, Italy
[5] Ctr Riferimento Trapianti Emila Romagna, Bologna, Italy
[6] Ctr Nazl Trapianti, Rome, Italy
关键词
liver transplantation; hepatocellular carcinoma; recurrences; de novo tumors;
D O I
10.1097/01.pas.0000143609.85487.36
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Distinction between recurrent and de novo hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT) bears important clinical and therapeutic implications. Techniques for molecular profiling of clinically suspected de novo and recurrent HCC are required since the histological/clinical discrimination of donor vs. recipient tumor origin is difficult. Multiple PCR amplification of 16 highly polymorphic short tandem repeat (STR) DNA sequences (routinely used for paternity and forensic assays) was applied in two patients who developed a second HCC after OLT. In both patients the technique provided reliable evidence that the two second HCC were recurrences of the primary tumor. Multiple STR genetic allelotyping is an effective tool for clear-cut discrimination of donor/recipient origin of a second HCC after OLT. Its application could be of great therapeutic relevance for such OLT patients.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 11 条
[1]   Delayed recurrence of hepatocellular carcinoma after liver transplantation: Detection of origin by chromosomal analysis [J].
Al-Joundi, T ;
Gibson, S ;
Brunt, EM ;
Shakil, O ;
Lee, RS ;
Di Bisceglie, AM .
LIVER TRANSPLANTATION, 2000, 6 (03) :374-375
[2]  
BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393
[3]   Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma [J].
Finkelstein, SD ;
Marsh, W ;
Demetris, AJ ;
Swalsky, PA ;
Sasatomi, E ;
Bonham, A ;
Subotin, M ;
Dvorchik, I .
HEPATOLOGY, 2003, 37 (04) :871-879
[4]   Donor origin of de novo hepatocellular carcinoma in hepatic allografts [J].
Flemming, P ;
Tillmann, HL ;
Barg-Hock, H ;
Kleeberger, W ;
Manns, MP ;
Klempnauer, J ;
Kreipe, HH .
TRANSPLANTATION, 2003, 76 (11) :1625-1627
[5]  
Holt CL, 2002, J FORENSIC SCI, V47, P66
[6]   Survival after liver transplantation for hepatocellular carcinoma [J].
Khakhar, A ;
Solano, E ;
Stell, D ;
Bloch, M ;
Dale, C ;
Burns, P ;
Ghent, C ;
Quan, D ;
McAlister, V ;
Marotta, P ;
Wall, WJ .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) :2438-2441
[7]   Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: Biologic and therapeutic implications [J].
Kirimlioglu, H ;
Dvorchick, I ;
Ruppert, K ;
Finkelstein, S ;
Marsh, JW ;
Iwatsuki, S ;
Bonham, A ;
Carr, B ;
Nalesnik, M ;
Michalopoulos, G ;
Starzl, T ;
Fung, J ;
Demetris, A .
HEPATOLOGY, 2001, 34 (03) :502-510
[8]   Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [J].
Mazzaferro, V ;
Regalia, E ;
Doci, R ;
Andreola, S ;
Pulvirenti, A ;
Bozzetti, F ;
Montalto, F ;
Ammatuna, M ;
Morabito, A ;
Gennari, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) :693-699
[9]   De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis [J].
Saxena, R ;
Ye, MQ ;
Emre, S ;
Klion, F ;
Nalesnik, MA ;
Thung, SN .
LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (01) :81-82
[10]   Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation [J].
Schlitt, HJ ;
Neipp, M ;
Weimann, A ;
Oldhafer, KJ ;
Schmoll, E ;
Boeker, K ;
Nashan, B ;
Kubicka, S ;
Maschek, H ;
Tusch, G ;
Raab, R ;
Ringe, B ;
Manns, MP ;
Pichlmayr, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :324-331